Trial Profile
A Study Assessing Resistance-Associated Variants (RAVs) In Hepatitis C Infected Patients Receiving Dual Oral Therapy With Daclatasvir/Asunaprevir By A Two-Hit Mechanism.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Therapeutic Use
- 12 Jan 2017 New trial record